Valeant goes on defensive against investor critics
It is publicly revealing for the first time the benefits that it gets from some price increases; says it has not been as dependent on drug price increases as analysts' reports claim
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
San Francisco
AMID an intensifying debate over drug price increases that has brought its business practices to the forefront, Valeant Pharmaceuticals International Inc fired back at critics in the investment community, publicly revealing the benefits that it gets from some price hikes for the first time.
Democrats in the US House of Representatives are pushing to subpoena the company for documents relating to drug price increases, causing Valeant shares to tumble. Morgan Stanley chimed in last week, saying that the company is more susceptible to political scrutiny than other drugmakers because it increases list prices more opportunistically. The criticism has added volume to a small chorus of bearish investment researchers dating back months, though most major Wall Street analysts still rate the stock a "buy".
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
Loyang Valley sold for S$880 million to SingHaiyi-led consortium
